293 related articles for article (PubMed ID: 25190197)
1. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.
Soler-Palacín P; Gasó-Gago I; Fernández-Polo A; Martín-Nalda A; Oliveras M; Martinez-Cutillas J; Figueras C
J Clin Immunol; 2014 Nov; 34(8):1015-7. PubMed ID: 25190197
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
[No Abstract] [Full Text] [Related]
3. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Experience of Subcutaneous Immunoglobulin Therapy in Pediatric Primary Immunodeficient Patients with Low and Normal Body Weight.
Gul Y; Kapakli H; Guner SN; Alan HB; Hazar E; Keles S; Reisli I
J Clin Immunol; 2022 Jan; 42(1):64-71. PubMed ID: 34617265
[TBL] [Abstract][Full Text] [Related]
6. Quality of Life Evaluation in Saudi Arabian Pediatric Patients with Primary Immunodeficiency Diseases Receiving 20% Subcutaneous IgG Infusions at Home.
Al-Saud B; AlRumayyan N; Alfattani A; Awwad SA; Al Saud D; Mohammed R; Albuhairi S; Elshorbagi S; Balhareth SS; Al-Dhekri H; Arnaout R; De Vol EB; Al-Mousa H
J Clin Immunol; 2023 Aug; 43(6):1360-1366. PubMed ID: 37145392
[TBL] [Abstract][Full Text] [Related]
7. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin.
Milota T; Bloomfield M; Kralickova P; Jilek D; Novak V; Litzman J; Posova H; Mrazova L; Poloniova J; Prucha M; Rozsival P; Rauschova V; Philipp G; Sediva A
Clin Ther; 2019 Nov; 41(11):2231-2238. PubMed ID: 31564514
[TBL] [Abstract][Full Text] [Related]
8. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.
Martin A; Lavoie L; Goetghebeur M; Schellenberg R
Transfus Med; 2013 Feb; 23(1):55-60. PubMed ID: 23167310
[TBL] [Abstract][Full Text] [Related]
9. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
[TBL] [Abstract][Full Text] [Related]
10. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin replacement treatment by rapid subcutaneous infusion.
Gaspar J; Gerritsen B; Jones A
Arch Dis Child; 1998 Jul; 79(1):48-51. PubMed ID: 9771252
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.
Bezrodnik L; Gómez Raccio A; Belardinelli G; Regairaz L; Díaz Ballve D; Seminario G; Moreira I; Riganti C; Cantisano C; Díaz H; Di Giovanni D
J Clin Immunol; 2013 Oct; 33(7):1216-22. PubMed ID: 23846854
[TBL] [Abstract][Full Text] [Related]
13. Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".
Bienvenu B; Cozon G; Hoarau C; Pasquet M; Cherin P; Clerson P; Hachulla E; Crave JC; Delain JC; Jaussaud R
Orphanet J Rare Dis; 2016 Jun; 11(1):83. PubMed ID: 27334100
[TBL] [Abstract][Full Text] [Related]
14. Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese.
Kan AKC; Leung GMK; Chiang V; Au EYL; Lau CS; Li PH
Front Immunol; 2022; 13():984110. PubMed ID: 36591300
[TBL] [Abstract][Full Text] [Related]
15. Why I use subcutaneous immunoglobulin (SCIG).
Shapiro RS
J Clin Immunol; 2013 Jan; 33 Suppl 2():S95-8. PubMed ID: 23264027
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
Visentin A; Molinari MC; Pravato S; Cellini A; Angotzi F; Cavaretta CA; Ruocco V; Imbergamo S; Piazza F; Proietti G; Mauro FR; Trentin L
Curr Oncol; 2022 Dec; 30(1):274-283. PubMed ID: 36661671
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis.
Shapiro R
J Clin Immunol; 2010 Mar; 30(2):301-7. PubMed ID: 20082124
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
[TBL] [Abstract][Full Text] [Related]
19. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
[TBL] [Abstract][Full Text] [Related]
20. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.
Kobayashi RH; Gupta S; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Turpel-Kantor E; Litzman J
Front Immunol; 2019; 10():40. PubMed ID: 30778345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
